Lenalidomide and the Risk for Second Cancers in MyelomaLenalidomide and the Risk for Second Cancers in Myeloma

The combination of lenalidomide and melphalan significantly increases the risk for hematologic second malignancies and should be avoided. Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news